Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.

Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Syndax Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Clinical Trials sector. The company focuses on Biotechnology and has secured $192.9B in funding across 240 round(s). With a team of 101-250 employees, Syndax Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Syndax Pharmaceuticals, raised $9.0M. Discover more about their projects, partnerships, and impact on our platform.